BaxDigm, 4-party cooperation MOU signed for 'rapid development of highly pathogenic avian influenza vaccine'

VAXDIGM announced on the 4th that it signed a memorandum of understanding (MOU) for cooperation in the development of a highly pathogenic avian influenza vaccine against H5N1 with the team led by Professor Choi Seong-il of Yonsei University College of Medicine, Korea Vaccine, and the team led by Professor Yuk Seong-su of Chungbuk National University College of Medicine.

This agreement ceremony was held recently at the IBK Industrial Bank Hall in Baekyangnuri, Yonsei University, and was attended by representatives and officials from each organization. The agreement is significant in that it combines domestically developed platform technology with the expertise of each organization, with the goal of strengthening domestic vaccine development capabilities.

The main content of the agreement is to establish a system for the four organizations to cooperate in the development of highly pathogenic avian influenza vaccines. They will closely cooperate in the areas of vaccine technology and platform development, production of non-clinical and clinical drug products, quality verification, safety, efficacy and quality assessment in non-clinical animal models, and approval and implementation of clinical trials.

Kim Sung-jae, CEO of BaxDigm, said, “The H5N1 avian influenza virus has spread to mammals, and there have been deaths in the United States. As it has spread worldwide through migratory birds, concerns about another pandemic are growing,” and added, “Through this agreement, we expect to be able to accelerate vaccine development by pooling the expertise of each organization.” He added, “We will quickly develop a vaccine to secure Korea’s vaccine sovereignty and contribute to global health.”

Ha Sung-bae, CEO of Korea Vaccine, said, “Through this agreement, we expect to be able to supply high-quality, safe vaccines by combining Baxdime’s rapid development platform, Yonsei University’s research experience, and Chungbuk National University’s evaluation facilities,” adding, “We will also be able to provide high-quality vaccines to low- and middle-income countries where it is difficult to supply mRNA vaccines.”

• See more related articles